Clinical Trial Update: Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 study of Epetraborole for treatment-refractory Mycobacterium avium complex lung disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Avium Complex Lung Disease

Drugs mentioned

• Epetraborole (epetraborole)

Snippet

Sponsor: AN2 Therapeutics, Inc | Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease | Phase 2, Phase 3 | Status: TERMINATED